文献速递肝病消化道肿瘤与早癌

卡瑞利珠单抗联合阿帕替尼±TACE一线治疗晚期肝细胞癌

Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First-Line Treatment for Advanced Hepatocellular Carcinoma.
PubMed 文献 · Aliment Pharmacol Ther · 2026-03-31

这项全国多中心回顾性队列研究纳入252例晚期肝细胞癌患者,比较TACE联合卡瑞利珠单抗和阿帕替尼(T-C-A)与卡瑞利珠单抗和阿帕替尼(C-A)的疗效与安全性。经sIPTW后,T-C-A组中位OS为24.2个月,显著长于C-A组的15.2个月;中位PFS为10.1个月对4.9个月;3/4级不良事件发生率分别为12.0%和14.5%。

要点

  • T-C-A组中位OS 24.2个月,显著优于C-A组15.2个月。
  • T-C-A组中位PFS 10.1个月,显著优于C-A组4.9个月。
  • 两组3/4级不良事件发生率相近,安全性可接受。

核心结论

  • TACE联合卡瑞利珠单抗和阿帕替尼一线治疗晚期肝细胞癌可能带来生存优势,且安全性可接受。

研究设计与样本

  • 全国多中心回顾性队列研究,纳入2018年1月至2022年12月接受T-C-A或C-A治疗的晚期肝细胞癌患者,共252例(T-C-A组183例,C-A组69例),采用稳定逆概率治疗加权(sIPTW)减少偏倚。

主要发现

  • 经sIPTW后,T-C-A组中位OS为24.2个月(95%CI:21.4-33.4),C-A组为15.2个月(95%CI:9.8-21.0),p<0.001。
  • 经sIPTW后,T-C-A组中位PFS为10.1个月(95%CI:8.8-12.2),C-A组为4.9个月(95%CI:4.0-12.5),p<0.001。
  • T-C-A组客观缓解率(ORR)高于C-A组。
  • T-C-A组3/4级不良事件发生率为12.0%,C-A组为14.5%。

临床怎么用

  • 对于晚期肝细胞癌一线治疗,可考虑在卡瑞利珠单抗和阿帕替尼基础上联合TACE,以改善生存且不显著增加严重不良事件。

局限性

  • 本研究为回顾性队列研究,尽管采用sIPTW,仍可能存在未测量的混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This real-world study aimed to evaluate and compare the efficacy and safety of two treatment strategies for advanced hepatocellular carcinoma (HCC): transarterial chemoembolisation (TACE) combined with camrelizumab and apatinib versus camrelizumab and apatinib alone. METHODS: In this nationwide, multi-centre retrospective cohort study, data were collected on patients with advanced HCC who received either TACE combined with camrelizumab and apatinib (T-C-A) or camrelizumab and apatinib alone (C-A) between January 2018 and December 2022. To reduce potential bias, stabilised inverse probability of treatment weighting (sIPTW) was applied. The primary outcome was overall survival (OS), while secondary outcomes included progression-free survival (PFS), objective response rate (ORR) based on RECIST v1.1 criteria, and safety. RESULTS: A total of 252 HCC patients were included (T-C-A group, n = 183; C-A group, n = 69). Among them, 210 were males and 42 were females, with a median age of 54 years. After sIPTW, the median OS was significantly longer in the T-C-A group compared to the C-A group (24.2 months [95% CI: 21.4-33.4] vs. 15.2 months [95% CI: 9.8-21.0]; p < 0.001). The T-C-A group also demonstrated a significantly improved median PFS of 10.1 months [95% CI: 8.8-12.2], compared to 4.9 months [95% CI: 4.0-12.5] in the C-A group (p < 0.001). Further, the ORR was higher in the T-C-A group. Grade 3/4 adverse events were reported in 12.0% of patients in the T-C-A group and 14.5% in the C-A group. CONCLUSION: The combination of TACE with camrelizumab and apatinib suggests potential survival advantages for patients with advanced HCC while maintaining an acceptable safety profile.(Study series number CHANCE 2311).

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Ding R, Bai JF, Jin ZC, et al. Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First-Line Treatment for Advanced Hepatocellular Carcinoma. Aliment Pharmacol Ther. 2026. PMID: 41915429. doi:10.1111/apt.70612

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。